PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) (the “Company” or “PreveCeutical”), is pleased to provide an update on the soluble gel (“Sol-gel”) drug delivery research and development program (the “Sol-gel Program”), that involves testing and formulating an array of cannabis strains for the development and commercialisation of cannabinoid-based Sol-gels. The Sol-gels are administered using a custom applicator device (the “Sol-gel Applicator”) for direct and sustained nose-to-brain drug delivery.

Achieving patient benefit from use of medicinal cannabis for the management of central nervous system (the “CNS”) conditions, such as epilepsy, anxiety and depression, is reliant upon achieving effective and sustained delivery of the cannabis-based therapeutic to brain tissue. When taken orally medicinal cannabis can cause gastrointestinal upset, and when absorbed across the gut it is rapidly broken down by enzymes. As common drug delivery methods do not provide effective and sustained delivery to the brain, the delivery of cannabinoids to the CNS is a universal problem. PreveCeutical is pleased to announce that it expects to address this issue through its Sol-gel platform and Sol-gel Applicator device for direct nose-to-brain delivery of cannabis-based therapeutics.


Traditional liquid nasal sprays are not retained in the nasal cavity for any appreciable time, and are only capable of generating random spray and deposition profiles as depicted in Figure 1a and Figure 1b, respectively.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/5434/41134_prev1a.jpg

Figure 1a Liquid spray profile into adult human nasal cast from applicator device (no inhalation, cast temperature 34 °C).

To view an enhanced version of Figure 1a, please visit:
https://orders.newsfilecorp.com/files/5434/41134_prev1a_en.jpg

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/5434/41134_prev1b.jpg

Figure 1b Liquid deposition profile into adult human nasal cast from applicator device (no inhalation, cast temperature 34 °C).

To view an enhanced version of Figure 1b, please visit:
https://orders.newsfilecorp.com/files/5434/41134_prev1b_en.jpg

In contrast, the Company’s Sol-gel Applicator generates a precise spray profile that directs the Sol-gel formulation high into the upper nasal cavity (Figure 2a), where it remains following rapid gelation (Figure 2b). This is an important development, as the region targeted by the Sol-gel is adjacent to the olfactory epithelium (depicted by red arrows in the figures below), which serves as a direct passage for molecules into the brain.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/5434/41134_prev2a.jpg

Figure 2a Sol-gel spray profile into adult human nasal cast from applicator device (no inhalation, cast temperature 34 °C).

To view an enhanced version of Figure 2a, please visit:
https://orders.newsfilecorp.com/files/5434/41134_prev2a_en.jpg

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/5434/41134_prev2b.jpg

Figure 2b Sol-gel deposition profile in adult human nasal cast from applicator device (no inhalation, cast temperature 34 °C).

To view an enhanced version of Figure 2b, please visit:
https://orders.newsfilecorp.com/files/5434/41134_prev2b_en.jpg

To exemplify the Sol-gel and Sol-gel Applicator’s capabilities, an inhalation model was developed to mimic the inhalation action performed by patients when using nasal sprays, which combines an action of simultaneously spraying into a nostril accompanied by steady and deep nasal inhalation.

In the inhalation model, liquid sprays and Sol-gel sprays were compared for their delivery high into the nasal cavity along the target region, the olfactory epithelia. As shown in Figure 3a, the liquid spray profile shows random spray distribution with distinct large droplets, which is undesirable for the nose-to-brain delivery of therapeutics. In stark contrast, the Sol-gel formulation (Figure 3b) was drawn high into the nasal cavity, rapidly gelling and coating the target olfactory epithelium region. This encouraging development paves the way for the use of Sol-gels and the Sol-gel Applicator for direct nose-to-brain delivery.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/5434/41134_prev3a.jpg

Figure 3a Liquid spray generates a random droplet profile (inhalation model, cast temperature 34 °C).

To view an enhanced version of Figure 3a, please visit:
https://orders.newsfilecorp.com/files/5434/41134_prev3a_en.jpg

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/5434/41134_prev3b.jpg

Figure 3b Sol-gel spray profile gels and coats olfactory epithelia (inhalation model, cast temperature 34 °C).

To view an enhanced version of Figure 3b, please visit:
https://orders.newsfilecorp.com/files/5434/41134_prev3b_en.jpg

The following video links showcase the contrasting spray profiles, in real-time, between a liquid and a Sol-gel being dispersed using the Sol-gel Applicator.

Video link to liquid spray profile demonstration
Video link to Sol-gel spray profile demonstration

The Company’s Chief Research Officer, Dr. Harendra Parekh stated, “This is an important development for PreveCeutical, having demonstrated that its engineered Sol-gels and applicator device achieve delivery and retention directly at target tissue high in the nasal cavity, a feat that cannot be claimed by liquid sprays existing in the market currently. What’s more exciting is that this outcome opens the door for PreveCeutical to potentially deliver a host of therapeutics from nose-to-brain in a reliable and sustained manner, which remains a significant challenge for many companies, globally.”

The CBD Sol-gel formulations, when used with the Company’s custom Sol-gel Applicator, will facilitate prolonged delivery of cannabinoids to patients’ central nervous system. The Company’s medicinal cannabis division expects to be able to offer a broad product range that can be tailored to specific medical conditions. For example, the Company is currently developing a CBD Sol-gel formulation with a cannabinoid composition designed to treat patient anxiety (see news release dated August 8, 2018).

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilising organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9 is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the Company’s website.

For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: http://twitter.com/PreveCeuticals and Facebook: www.facebook.com/PreveCeutical.

On Behalf of the Board of Directors

“Stephen Van Deventer”
Chairman, CEO and President

For further information, please contact:

Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@PreveCeutical.com

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian and U.S. securities legislation, including the United States Private Securities Litigation Reform Act of 1995. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the completion of the Sol-gel Program, the development and testing of the Sol-gel formulations and the Sol-gel Applicator, the efficacy of the Company’s products, matters related to the Company’s current and planned research and development programs, including the Sol-gel Program, the Company’s anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as “plans”, “expects”, “may”, “intends”, “anticipates”, “believes”, “proposes” or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, risks and uncertainties relating to the inability of the Company, to, among other things, obtain any required governmental, regulatory or stock exchange approvals, permits, consents or authorizations required, including Canadian Securities Exchange acceptance of any planned future activities, commercialise therapeutic and diagnostic technologies, execute its proposed business plans, pursue business partnerships, complete its research programs as planned and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology, pharmaceutical or cannabis industries, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-to-time. These reports and the Company’s filings are available at www.sedar.com.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.

Click here to connect with PreveCeutical Medical Inc. (CSE:PREV, OTCQB:PRVCF, FSE:18H) for an Investor Presentation. 

Source: www.newsfilecorp.com

Strategic sale of non-core assets by Lobe adds non-dilutive capital and shareholder value

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce, further to its press release dated February 23, 2021, that it has completed the sale to Ionic Brands Corp. (“Ionic Brands”) of Lobe’s non-core cannabis assets relating to Washington-based Cowlitz County Cannabis Cultivation Inc. (“Cowlitz”) held by Lobe’s subsidiary vendor, Green Star Biosciences Inc. (the “Transaction”).

Keep reading... Show less

Adding to its existing presence on the west coast of the United States, all five KOIOS™ flavours and all four Fit Soda™ flavours will be carried in Metropolitan Market stores beginning on Monday, March 22, 2021. Serving the Seattle-Tacoma area (population 3.87 million), Metropolitan Market is one of five chains under its parent firm Good Food Holdings, which has a total of 51 stores in California, Oregon, and Washington State.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that beginning on Monday, March 22, 2021, Koios’ entire line of canned beverage products will be sold at all locations of Metropolitan Market, an urban format supermarket chain in the Seattle-Tacoma area of Washington State. In Q1 2021, the Company announced multiple placements of its beverage products with regional grocers in markets on the west coast of the United States including Market of Choice in Oregon Jensen’s in Southern California and major natural grocery chain Sprouts Farmers Market which has a substantial west coast presence with over one third of its locations (360+ stores across 23 states) in California as well as Washington State 1 . The Company has also recently announced other developments relating to its expansion efforts being undertaken in 2021 such as an in-house beverage canning facility and distribution agreements with regional and national wholesale partners.

Keep reading... Show less

Ensuring estoraTMpatients have seamless access to their high-quality medical cannabis products

World-Class Extractions Inc. (CSE:PUMP)(FRA:WCF)(OTCQB:WCEXF) (the “Company” or “World-Class”) is pleased to announce that its subsidiary Pineapple Express Delivery Inc. (“Pineapple Express Delivery” or “PED”), a leading logistics technology company offering compliant and secure delivery of controlled substances and regulated products, has partnered with CannTrust Inc. to bring same-day and next-day delivery to estoraTM medical cannabis patients in Ontario

Keep reading... Show less

American cannabis sales hit US$17.5 billion in 2020, a research group’s new study shows.

Meanwhile, a Canadian cannabis producer began offering CBD beverages in the US, another move that shows how interested Canadians are in the overall US cannabis market at the moment.

Keep reading... Show less

An Emerging Markets Sponsored Commentary

Some pretty important news out of health and wellness; beverage and natural products company BevCanna Enterprises Inc. (CSE:BEV, Q:BVNNF, FSE:7BC) this week. For those of you following the Company with us, stay tuned.

Keep reading... Show less